Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | AMG 673: novel half-life extended anti-CD33/CD3 BiTE in R/R AML

Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, discusses the preliminary results from a phase I first-in-human study (NCT03224819) of AMG 673, a novel half-life extended anti-CD33/CD3 bispecific T-cell engager (BiTE) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Prof. Subklewe explains that the most common treatment-related adverse event was cytokine release syndrome (CRS). Additionally, assessment of bone marrow in treated patients showed a decrease in blasts and dose-related increases in Cmax and AUC were observed following AMG 673 infusions. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.